Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784653 | 1.00 | CTSS (0.40) | CTSSCYP11B1HDAC8HTR6CYP11B2 | |
| SCHEMBL6786125 | 0.89 | CYP11B1 (0.40) | CTSSCYP11B1HTR6CYP11B2LMNA | |
| SCHEMBL6794275 | 0.89 | CYP11B1 (0.40) | CTSSCYP11B1HTR6CYP11B2LMNA | |
| SCHEMBL6782094 | 0.88 | CYP11B1 (0.44) | CTSSCYP11B1CYP11B2LMNAHDAC1 | |
| SCHEMBL6783038 | 0.85 | MMP13 (0.42) | HDAC8LMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL6783034 | 0.85 | MMP13 (0.42) | HDAC8LMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL6787489 | 0.82 | MMP13 (0.45) | CTSSHDAC8CYP11B2HDAC3HDAC4 | |
| SCHEMBL6786877 | 0.82 | HDAC3 (0.37) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6783023 | 0.82 | HDAC3 (0.41) | HDAC8CYP11B2LMNAHDAC3HDAC4 | |
| SCHEMBL6787492 | 0.82 | MMP13 (0.45) | CTSSHDAC8CYP11B2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | claimed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | claimed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | claimed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | claimed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | claimed |
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PSEN1, PSEN2, IAPP | CTSS 4756/4885CYP11B1 566/4885HDAC8 4846/4885 |
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CTSS 56/4885CYP11B1 2766/4885HDAC8 160/4885 |
| US-20030216404-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CTSS 56/4885CYP11B1 2766/4885HDAC8 160/4885 |
| US-20040266764-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CTSS 56/4885CYP11B1 2766/4885HDAC8 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.